Last reviewed · How we verify
smallpox vaccine CJ-50300
CJ-50300 is a recombinant vaccinia virus-based vaccine designed to induce immune responses against smallpox virus antigens.
CJ-50300 is a recombinant vaccinia virus-based vaccine designed to induce immune responses against smallpox virus antigens. Used for Smallpox prevention and immunization.
At a glance
| Generic name | smallpox vaccine CJ-50300 |
|---|---|
| Also known as | CJ-53300 |
| Sponsor | Seoul National University Hospital |
| Drug class | Recombinant viral vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a modified vaccinia virus vector expressing smallpox antigens to stimulate both cellular and humoral immunity. This approach aims to provide protective immunity against smallpox while potentially offering improved safety and immunogenicity compared to traditional live vaccine platforms. The recombinant design allows for controlled antigen presentation and reduced reactogenicity.
Approved indications
- Smallpox prevention and immunization
Common side effects
- Injection site reactions
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers (PHASE3)
- Safety and Efficacy of CJ-50300 in Healthy Volunteers (PHASE2, PHASE3)
- Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers (PHASE3)
- Safety and Immunogenicity of CJ-50300 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- smallpox vaccine CJ-50300 CI brief — competitive landscape report
- smallpox vaccine CJ-50300 updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI